CeleCor Therapeutics
John Maraganore is a seasoned executive in the biotechnology field with extensive experience as Chief Executive Officer at Alnylam Pharmaceuticals from 2002 to 2021 and various leadership roles at prominent companies. Currently, Maraganore operates as an Executive Advisor at Blackstone and holds multiple positions including Venture Partner at Atlas Venture and ARCH Venture Partners, Principal CEO at JMM Innovations LLC, and Executive Partner at RTW Investments, LP. Previous roles include Senior Vice President at Millennium Pharmaceuticals and multiple senior positions at Biogen. Maraganore holds a Ph.D., M.S., and B.A. in Biochemistry and Molecular Biology from the University of Chicago.
This person is not in the org chart
This person is not in any offices
CeleCor Therapeutics
CeleCor Therapeutics develops a RUC-4 novel small molecule inhibitor designed to be the first point of contact treatment for segment elevated myocardial infarction. The molecule inhibitor uses a thrombolytic agent for percutaneous coronary intervention that can be administered subcutaneously by auto-injector, enabling decreased mortality and laterdevelopment of heart failure.